To validate our strategy, we indeed evaluated the localization and activation status of β-catenin in two APC mutant CRC cell lines (DLD-1 and LoVo), two CRC cell lines with no Wnt pathway relevant mutations (RKO and HCT8), a hepatocellular carcinoma (HCC) cell line with an AXIN1 mutation (Hep3B), a HCC cell line with a CTNNB1 mutation (HepG2), and a CRC cell line with a CTNNB1 mutation (LS174T). The gene discussed is APC; the disease is colorectal carcinoma.